Capricor Therapeutics met with the FDA last week for a type A meeting, during which CEO Linda Marbán aimed to explain to the ...

First-in-human trial of Capricor’s StealthX™ vaccine initiated under HHS’s Project NextGenTrial conducted and funded by the ...

Capricor Therapeutics (CAPR) announced that the first subjects have been dosed in a Phase 1 clinical trial evaluating its StealthX exosome-based ...

Replimune (NASDAQ:REPL), and Capricor Therapeutics (NASDAQ:CAPR), which faced regulatory setbacks from the FDA’s biologics division, recently witnessed sharp increases in their share prices on Tuesday ...

Despite zero revenue and increased losses, Capricor Therapeutics Inc (CAPR) focuses on strategic initiatives and regulatory ...

Capricor Therapeutics management emphasized continued confidence in regulatory progress for deramiocel, with commercial, manufacturing, and medical leadership preparations underway to support a ...

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit ...

Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of ...

Capricor Therapeutics (NASDAQ: CAPR) shares dropped after the U.S. FDA inspected its San Diego manufacturing facility for the cell therapy candidate, deramiocel, and issued a Form 483 with various ...

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases.

Capricor Media Contact: Raquel Cona KCSA Strategic Communications rcona@kcsa.com 212.896.1204 Capricor Company Contact: AJ Bergmann, Chief Financial Officer abergmann@capricor.com 858.727.1755 ...

Capricor Therapeutics's Current Market Status With a volume of 1,798,587, the price of CAPR is up 5.46% at $21.24. RSI indicators hint that the underlying stock may be overbought.